市場調查報告書
商品編碼
1270938
2023-2030 年全球血液學市場Global Hematology Analyzer Market 2023-2030 |
血細胞計數器的全球市場規模預計到 2022 年將達到 73 億美元,到 2030 年將達到 115 億美元,預測期內(2023-2030 年)的複合年增長率為 6.6%。 血細胞計數器是一種高度專業化的計算機化機器,可以計算血液樣本中不同類型的紅細胞和白細胞、血小板、血紅蛋白和血細胞比容的數量。 它有一個可編程的自動報警系統來指示超出參考範圍的結果。 血液分析儀涉及疾病的檢測、監測、預後和篩查,廣泛應用於血友病、血癌、血栓等各種與血液有關的疾病。 它還包括血液學診斷的疾病,如白血病、貧血、輸血和惡性淋巴瘤。
貧血、血癌、出血性疾病和血液感染等血液疾病患病率上升是推動市場增長的主要因素。 此外,血細胞計數器的技術進步、對自動化血細胞計數器的需求增加以及對高靈敏度血細胞計數器的日益偏好進一步推動了血細胞計數器市場的增長。 然而,由於先進的功能和自動化,血細胞計數器的高成本可能會阻礙市場增長。 另一方面,新興國家的增長機會有望為血液學市場參與者提供有利可圖的機會。
The global hematology analyzer market size was valued at $7.3 billion in 2022, and is projected to reach $11.5 billion by 2030, registering a CAGR of 6.6% during the forecast period (2023-2030). Hematology analyzers are computerized, highly specialized machines that count the number of different types of red and white blood cells, blood platelets, hemoglobin, and hematocrit levels in a blood sample. They include programmable automated alarm systems for indicating results outside the reference range. Hematology analyzers are concerned with detection, monitoring of diseases, prognosis and subsequent screening and are extensively used against various blood related diseases such as hemophilia, blood cancer and blood clots. Other diseases include leukemia, anemia, blood transfusion, malignant lymphomas, and others where hematology diagnosis is used.
Rising prevalence of blood disorders such as anemia, blood cancers, hemorrhagic conditions, and infections in the blood, is a major factor that drives the growth of the market. In addition, technological advancements in hematology analyzers, and growth in demand for automated hematology analyzers coupled with rising preference toward high sensitivity hematology analyzers further fuel the growth of the hematology analyzer market. However, high cost of hematology analyzers owing to advanced features and automation may hinder the growth of the market. In contrast, growth opportunities in emerging economies are expected to offer lucrative opportunities for players in the hematology analyzer market.
The global hematology analyzer market is segmented into product and services, type, and end-users. Based on product & service, it is classified into instruments, reagent & consumables, and services. By type, it is segmented into fully-automated hematology analyzer and semi-automated hematology analyzer. Based on the end user, the market is further sub-segmented into hospitals, clinical laboratories, research institutes, and others. Among the application segment, the fully-automated sub-segment is expected to cater prominent market share over the forecast period. Among product and services, the reagent & consumables market is expected to hold a significant market share due to increasing adoption of reagent and consumables in clinical laboratories for blood cell counts, coagulation testing, other hematology tests, control, and calibration.
Among type, fully automated segment is expected to hold a prominent share in the market during the forecast period. This is attributed to growing preference for automated hematology instruments, along with increasing technological advancements, and the combination of basic flow-cytometry techniques in automated hematology analyzers. Furthermore, clinical laboratories segment is expected to hold considerable share throughout the forecast period owing to presence of high-quality equipment in clinical laboratories and the accurate results obtained from them.
The global hematology analyzer market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for particular region or country level as per the requirement. Among these, the North American regional market is expected to cater prominent growth over the forecast period, owing to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the diagnostic industry.
The Asia-Pacific region is expected to hold a prominent share in the market during the forecast period owing to opportunities offered by market key players. Furthermore, the growing healthcare infrastructure, increasing prevalence of blood diseases, rising disposable incomes, well-established presence of domestic companies, and aging population in the region are further accelerating the growth of the market. In addition, factors such as increase in population and growth in the economies of developing countries such as India and China, are also supporting the growth of the hematology analyzer market in Asia. Technological advancements coupled with supportive investments and funds by the government, especially in developing countries, such as India and China, are also expected to contribute to market growth.
The major companies serving the global hematology analyzer market include Abbott Laboratories, Horiba Ltd., Siemens Healthcare GmBH, Sysmex Corp., Danaher Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2022, Mindray launched the BC-700 Series, a revolutionary hematology analyzer series that includes both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests. Moreover, in April 2022, Sysmex Europe launched its new three-part differential system 'XQ-320 XQ-Series Automated Hematology Analyzer', answering the needs of this important high-volume market segment. XQ-320 brings excellence in quality to a diverse range of clinical laboratory environments with reliable technology and a new level of usability. Users can get a first real impression of the new instrument at the EuroMedLab exhibition in Munich, Germany.